Acute Respiratory Distress Syndrome (ARDS)Masi-ARDSNCT06667375
Conventional Versus Automated Bag-based Mechanical Ventilator to Support ARDS Patients
An observational study of Acute Respiratory Distress Syndrome (ARDS), run by Fanny Lys Casado Pena at 1 site in Peru.
Trial summary
This study evaluates the extubation success and compares the survival rate in patients with signs of Covid-19 intubated with Masi, a novel type of mechanical ventilator, or with other conventional ventilators admitted in the ICU of a reference hospital in Lima, Peru between January and August 2021. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Respiratory Distress Syndrome (ARDS)
- How many people
- 87 participants
- Where
- 1 sitePeru
- Study dates
- 19 Jan 2021to 20 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Data from patients that were diagnosed with Covid-19, intubated and connected to a mechanical ventilator in the ICU between January 19, 2021 to August 27, 2021 which coincides with the second Peruvian wave of the Covid-19 pandemics in the Hospital Vitarte II in Lima
Who may be able to join
- Patients hospitalized to ICU requiring mechanical ventilation during COVID-19 pandemic
- Over 18 years old
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Description of the Performance of the "Masi" Mechanical Ventilator in a Hospital in Lima: Case Series
This study evaluates the extubation success and compares the survival rate in patients with signs of Covid-19 intubated with Masi, a novel type of mechanical ventilator, or with other conventional ventilators admitted in the ICU of a reference hospital in Lima, Peru between January and August 2021. The Masi mechanical ventilator works by automating a resuscitation bag with promising preclinical results. The key features of Masi are its low manufacturing cost, low dependence on a supply of high volumes of oxygen, low oxygen consumption, flexibility between non-invasive and invasive ventilation, and extended range of working environmental altitudes compared to commercially available ventilators. A retrospective study of variables and outcomes was done. The main goal of this study is to compare the survival rate of respiratory failure patients supported either with Masi or conventional ventilators at Hospital Vitarte II in Lima between January and August 2021.
Read the detailed description
The translation of novel technologies for Intensive Care Units (ICU) including mechanical ventilators has been mostly about incremental improvements through increasing features assuming the presence of highly trained personnel and dedicated infrastructure such as permanent power supply and high oxygen flow. Despite the long history of use of mechanical ventilators, the Covid-19 pandemic demanded innovation to meet worldwide demands for this type of life support equipment. The inadequacy of the commercially available ventilators has been mostly attributed to weak fabrication and supply chains and inconsistencies between the required sanitary infrastructure and human resources available for which most commercial ventilators have been designed. Diverse approaches addressed the design and development of low-cost and more available mechanical ventilators worldwide achieving various levels of clinical implementation.
In Peru, the Masi (companion in Quechua) ventilator was developed based on concepts of the MIT Emergency Ventilator (MIT E-Vent) by automating a resuscitation bag. The Masi initiative showed promising pre-clinical results that allowed the production of more than 250 units under an exceptional permit to be used clinically in Peru only when no other ventilators were available. The key features of this technology are its low manufacturing cost, low oxygen consumption, flexibility between non-invasive and invasive ventilation, and extended range of working environmental altitudes compared to commercially available ventilators. Clinical characteristics, blood chemistry information, respiratory parameters, and survival rates were analyzed for 77 patients (42 ventilated by Masi, 35 ventilated by commercial ventilators).
This is an observational retrospective cohort study. The study protocol was approved by the Research Ethics Committee for Life Sciences and Technology of the PUCP (002-2021-CEICVyTech/PUCP) on September 23, 2021. A total of one hundred and three (103) patients were admitted to the ICU between January 19, 2021 until August 27, 2021, which coincides with the second Peruvian wave of the Covid-19 pandemic in the Hospital Vitarte II in Lima, Peru. Data from patients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to a mechanical ventilator in the ICU were de-identified for this study. From the 132 variables collected into the Electronic Health Records, only 120 selected variables were transcribed into an electronic database (Microsoft Excel V). The data was standardized and entered by a physician trained in Good Clinical Practice (Data Entry Investigator) following a Data Dictionary.
After data cleanup, this study retrospectively analyzed data from eighty-seven (87) patients who had a positive Covid-19 diagnosis and used a mechanical ventilator machine. According to the Peruvian regulatory agency, DIGEMID, Masi was indicated only when no conventional ventilator was available, and a patient needed one as determined by the ICU physician. The physicians used their criteria to prescribe Masi or other available ventilator brands.
During the described period, the ICU of the Hospital Vitarte II had seven beds and four conventional ventilators: Evolution (EVL100001-T-NF), Vela (16532-07), Newport (e360) and Dragger (Savina 300). Eight new individually validated ventilators known as Masi were provided to the ICU, and the medical personnel were trained regarding its clinical use. This device was approved to be used in Peru during the sanitary emergency by the local competent authority: Dirección General de Medicamentos, Insumos y Dispositivos Médicos (DIGEMID, Spanish acronym) based on preclinical evidence of safety.
To avoid bias derived from the convenience sampling of a single-site study, the Data Entry Investigator reviewed the medical charts corresponding to every patient (n=103) admitted into ICU at the site during the study range across Masi before selecting the charts to be included. A selection was made from the initial 132 variables recorded based on relevance for the present study. Variables from the initial database were uploaded into R studio. The variables and values were reviewed by two independent data analysts and queried to the data entry assistant when necessary. The dataset was cleaned up, and variables were normalized and categorized. Each variable was evaluated with a univariate analysis followed by a bivariate analysis comparing different results between pre- and post-intubation, and post and last-intubation measurements. The main factors used for comparison were the respiratory parameters before and after the intubation between the mechanical ventilators Masi versus conventional. An additional analysis was done to compare survival rates by using the Kaplan-Meier estimator and COX analysis. A sensitivity analysis was done to each model to evaluate suitability for a non- parametric and semi-parametric test.
- Keywords
- Ventilators, Medical devices,, Data analysis, Technological innovation
- Medical subject headings
- Respiratory Distress Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Masi | Patients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to an automated-bag mechanical ventilator in the ICU | |
| Conventional | Patients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to a commercial mechanical ventilator in the ICU |
What is being measured
The primary outcome is the main question the study is designed to answer.
ICU discharge status
After being in the ventilator in the ICU what happened at extubation or censoring time.
Measured: Patients were followed 15 days (median)
Secondary outcomes (5)
Ventilator parameter: Oxygen Saturation (%)
Comparing Oxygen Saturation(%) between ventilators.
Measured: Patients were followed up 15 days (median)
Ventilator parameter: Respiratory rate (breaths/minute)
By comparing Respiratory rates between ventilators.
Measured: Patients were followed up 15 days (median)
Ventilator parameter: PaO2/FiO2 ratio
Comparing PaO2/FiO2 ratio between ventilators.
Measured: Patients were followed up 15 days (median)
Ventilator parameters: Tidal volumen (mL)
Comparing Tidal volumen between ventilators
Measured: Patients were followed up 15 days (median)
Ventilator parameters: PIP (mmHg)
Comparing PIP values between ventilators.
Measured: Patients were followed up 15 days (median)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Oct 2024
- Study start19 Jan 2021
- Primary completion27 Aug 2021
- Study completion20 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Respiratory Distress Syndrome (ARDS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 87 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fanny Lys Casado Pena
- Sponsor type
- University, hospital or other
- Collaborators
- EsSalud Hospital Vitarte (HOSPITAL II VITARTE ESSALUD)
- Responsible party
- Sponsor-investigator, Fanny Lys Casado Pena, Pontificia Universidad Catolica del Peru
- Investigators
- Fanny L Casado Peña, PhD, Principal investigator, Pontificia Universidad Catolica del PeruSergio Sánchez-Gambetta, MD, MSc, Principal investigator, Pontificia Universidad Catolica del Peru
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06667375
- Sponsor's protocol ID
- 002-2021-CEICVyTech/PUCP
- Acronym
- Masi-ARDS
- Status last verified
- Oct 2024
- First submitted
- 28 Oct 2024
- Last updated
- 31 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Pending to confirm with local team and local laws what IPD can be shared. An URL is also required once we check Yes; we dont have any URL ready.
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Description of the Performance of the "Masi" Mechanical Ventilator in a Hospital in Lima: Case Series
- ClinicalTrials.gov ID
- NCT06667375
- Acronym / sponsor ID
- Masi-ARDS / 002-2021-CEICVyTech/PUCP
- Keywords
- Ventilators, Medical devices,, Data analysis, Technological innovation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 87 participants (actual)
- Lead sponsor
- Fanny Lys Casado PenaUniversity, hospital or other
- Collaborators
- EsSalud Hospital Vitarte (HOSPITAL II VITARTE ESSALUD)
- Study start
- 19 Jan 2021 (actual)
- Primary completion
- 27 Aug 2021 (actual)
- Study completion
- 20 Dec 2022 (actual)
- First posted
- 31 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the extubation success and compares the survival rate in patients with signs of Covid-19 intubated with Masi, a novel type of mechanical ventilator, or with other conventional ventilators admitted in the ICU of a reference hospital in Lima, Peru between January and August 2021. The Masi mechanical ventilator works by automating a resuscitation bag with promising preclinical results. The key features of Masi are its low manufacturing cost, low dependence on a supply of high volumes of oxygen, low oxygen consumption, flexibility between non-invasive and invasive ventilation, and extended range of working environmental altitudes compared to commercially available ventilators. A retrospective study of variables and outcomes was done. The main goal of this study is to compare the survival rate of respiratory failure patients supported either with Masi or conventional ventilators at Hospital Vitarte II in Lima between January and August 2021.
Detailed description
The translation of novel technologies for Intensive Care Units (ICU) including mechanical ventilators has been mostly about incremental improvements through increasing features assuming the presence of highly trained personnel and dedicated infrastructure such as permanent power supply and high oxygen flow. Despite the long history of use of mechanical ventilators, the Covid-19 pandemic demanded innovation to meet worldwide demands for this type of life support equipment. The inadequacy of the commercially available ventilators has been mostly attributed to weak fabrication and supply chains and inconsistencies between the required sanitary infrastructure and human resources available for which most commercial ventilators have been designed. Diverse approaches addressed the design and development of low-cost and more available mechanical ventilators worldwide achieving various levels of clinical implementation.
In Peru, the Masi (companion in Quechua) ventilator was developed based on concepts of the MIT Emergency Ventilator (MIT E-Vent) by automating a resuscitation bag. The Masi initiative showed promising pre-clinical results that allowed the production of more than 250 units under an exceptional permit to be used clinically in Peru only when no other ventilators were available. The key features of this technology are its low manufacturing cost, low oxygen consumption, flexibility between non-invasive and invasive ventilation, and extended range of working environmental altitudes compared to commercially available ventilators. Clinical characteristics, blood chemistry information, respiratory parameters, and survival rates were analyzed for 77 patients (42 ventilated by Masi, 35 ventilated by commercial ventilators).
This is an observational retrospective cohort study. The study protocol was approved by the Research Ethics Committee for Life Sciences and Technology of the PUCP (002-2021-CEICVyTech/PUCP) on September 23, 2021. A total of one hundred and three (103) patients were admitted to the ICU between January 19, 2021 until August 27, 2021, which coincides with the second Peruvian wave of the Covid-19 pandemic in the Hospital Vitarte II in Lima, Peru. Data from patients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to a mechanical ventilator in the ICU were de-identified for this study. From the 132 variables collected into the Electronic Health Records, only 120 selected variables were transcribed into an electronic database (Microsoft Excel V). The data was standardized and entered by a physician trained in Good Clinical Practice (Data Entry Investigator) following a Data Dictionary.
After data cleanup, this study retrospectively analyzed data from eighty-seven (87) patients who had a positive Covid-19 diagnosis and used a mechanical ventilator machine. According to the Peruvian regulatory agency, DIGEMID, Masi was indicated only when no conventional ventilator was available, and a patient needed one as determined by the ICU physician. The physicians used their criteria to prescribe Masi or other available ventilator brands.
During the described period, the ICU of the Hospital Vitarte II had seven beds and four conventional ventilators: Evolution (EVL100001-T-NF), Vela (16532-07), Newport (e360) and Dragger (Savina 300). Eight new individually validated ventilators known as Masi were provided to the ICU, and the medical personnel were trained regarding its clinical use. This device was approved to be used in Peru during the sanitary emergency by the local competent authority: Dirección General de Medicamentos, Insumos y Dispositivos Médicos (DIGEMID, Spanish acronym) based on preclinical evidence of safety.
To avoid bias derived from the convenience sampling of a single-site study, the Data Entry Investigator reviewed the medical charts corresponding to every patient (n=103) admitted into ICU at the site during the study range across Masi before selecting the charts to be included. A selection was made from the initial 132 variables recorded based on relevance for the present study. Variables from the initial database were uploaded into R studio. The variables and values were reviewed by two independent data analysts and queried to the data entry assistant when necessary. The dataset was cleaned up, and variables were normalized and categorized. Each variable was evaluated with a univariate analysis followed by a bivariate analysis comparing different results between pre- and post-intubation, and post and last-intubation measurements. The main factors used for comparison were the respiratory parameters before and after the intubation between the mechanical ventilators Masi versus conventional. An additional analysis was done to compare survival rates by using the Kaplan-Meier estimator and COX analysis. A sensitivity analysis was done to each model to evaluate suitability for a non- parametric and semi-parametric test.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Masi | – | –Patients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to an automated-bag mechanical ventilator in the ICU |
| Conventional | – | –Patients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to a commercial mechanical ventilator in the ICU |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Data from patients that were diagnosed with Covid-19, intubated and connected to a mechanical ventilator in the ICU between January 19, 2021 to August 27, 2021 which coincides with the second Peruvian wave of the Covid-19 pandemics in the Hospital Vitarte II in Lima
Key inclusion criteria (2 listed)
- Patients hospitalized to ICU requiring mechanical ventilation during COVID-19 pandemic
- Over 18 years old
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
ICU discharge status
Time frame: Patients were followed 15 days (median)
After being in the ventilator in the ICU what happened at extubation or censoring time.
5 secondary outcomes
Ventilator parameter: Oxygen Saturation (%)
Time frame: Patients were followed up 15 days (median)
Ventilator parameter: Respiratory rate (breaths/minute)
Time frame: Patients were followed up 15 days (median)
Ventilator parameter: PaO2/FiO2 ratio
Time frame: Patients were followed up 15 days (median)
Ventilator parameters: Tidal volumen (mL)
Time frame: Patients were followed up 15 days (median)
Ventilator parameters: PIP (mmHg)
Time frame: Patients were followed up 15 days (median)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2024.
- Individual participant dataSharing planned: Undecided. Pending to confirm with local team and local laws what IPD can be shared. An URL is also required once we check Yes; we dont have any URL ready.
Related trials for Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Development and Prospective Validation of the AutoEIT Foundation Model for ARDS
ARDS (Acute Respiratory Distress Syndrome), Respiratory Failure
Not yet recruiting
The Hemodynamic Impact of High-frequency Oscillatory Ventilation and Periodic Sighs in Preterm Infants
Preterm, Respiratory Distress Syndrome in Premature Infant
Not yet recruitingPhase 2
Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults
Acute Respiratory Distress Syndrome, ARDS
Recruiting
Ventilator Pressure and Optimization of Compliance and Hemodynamics
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia
RecruitingObservational study
Pulmonary Immune Cell-microbiome Interactions in ARDS
ARDS, Human
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fanny L Casado Peña, PhD principal investigator
Pontificia Universidad Catolica del Peru
Sergio Sánchez-Gambetta, MD, MSc principal investigator
Pontificia Universidad Catolica del Peru
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Respiratory Distress Syndrome (ARDS), run by Fanny Lys Casado Pena at 1 site in Peru.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Peru. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ICU discharge status (time frame: Patients were followed 15 days (median)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024.